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Abstract
Background: Group A streptococcus (GAS) is the most common bacterial cause of sore throat. School-age children
bear the highest burden of GAS pharyngitis. Accurate diagnosis is difficult: the majority of sore throats are viral in
origin, culture-based identification of GAS requires 24–48 hours, and up to 15% of children are asymptomatic throat
carriers of GAS. The aim of this study was to develop a quantitative polymerase chain reaction (qPCR) assay for
detecting GAS pharyngitis and assess its suitability for clinical diagnosis.
Methods: Pharyngeal swabs were collected from children aged 3–18 years (n = 91) and adults (n = 36) located in
the Melbourne area who presented with sore throat. Six candidate PCR assays were screened using a panel of
reference isolates, and two of these assays, targeting speB and spy1258, were developed into qPCR assays. The qPCR
assays were compared to standard culture-based methods for their ability to detect GAS pharyngitis. GAS isolates
from culture positive swabs underwent emm-typing. Clinical data were used to calculate McIsaac scores as an
indicator of disease severity.
Results: Twenty-four of the 127 samples (18.9%) were culture-positive for GAS, and all were in children (26%). The
speB qPCR had 100% sensitivity and 100% specificity compared with gold-standard culture, whereas the spy1258
qPCR had 87% sensitivity and 100% specificity. Nine different emm types were found, of which emm 89, 3, and 28
were most common. Bacterial load as measured by qPCR correlated with culture load. There were no associations
between symptom severity as indicated by McIsaac scores and GAS bacterial load.
Conclusions: The speB qPCR displayed high sensitivity and specificity and may be a useful tool for GAS pharyngitis
diagnosis and research.
Background
Group A streptococcus (GAS; Streptococcus pyogenes) is
the most common bacterial cause of pharyngitis. GAS
pharyngitis is most common in school-age children,
affecting approximately 1 in 10 children per year [1]. In
addition to pain and discomfort, throat infection can
lead to suppurative complications such as otitis media
and peri-tonsillar abscess, and non-suppurative sequelae
such as rheumatic fever. GAS pharyngitis is a costly
disease to society due to medical care and absence from
school. In the United States, it is estimated that GAS
pharyngitis costs the community up to 500 million USD
per year [2].
Although GAS pharyngitis is usually self-limiting,
rapid and accurate detection is important, as early treat-
ment with appropriate antibiotics is known to reduce
symptom severity and duration, decrease transmission of
the organism, and reduce the risk of acute rheumatic
fever [3-6]. As most pharyngitis is viral in origin, accur-
ate diagnosis can reduce the unnecessary use of antibi-
otics and potential development of antibiotic resistance
[7,8]. However, accurate diagnosis of GAS pharyngitis is
difficult for a number of reasons. First, diagnosis of GAS
pharyngitis using clinical signs alone is unreliable; physi-
cians miss up to 50% of GAS pharyngitis cases and iden-
tify 20-40% of non-GAS sore throat cases as requiring
antibiotics [9]. A contributing factor to misdiagnosis is
that clinical presentation of GAS pharyngitis is variable;
for example, in a study in Egypt only 31% of children
with GAS pharyngitis had purulent exudates observed
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on clinical examination [10]. The Centor score [11] and
the McIsaac score [9] (a modified version of the Centor
score that takes patient age into account) use a combi-
nation of history and examination findings to aid clinical
diagnosis of GAS pharyngitis, improving sensitivity from
50% up to 85% overall and 97% in children. However,
specificity remains poor (67% in children) [9]. Second,
the standard procedure for laboratory detection of GAS,
culture on blood agar, typically requires 24–48 hours.
Third, many children are asymptomatic carriers of GAS,
with the prevalence of GAS throat carriage estimated at
12% [12].
Since the 1980s, commercial rapid antigen detection
tests (RADTs) have been available as a means of GAS
detection. The advantage of rapid diagnostic tests is that
they can be quickly performed in the physician’s office.
However, although RADTs have good specificity (>95%),
they often have reduced sensitivity (~85%) compared to
culture [13,14]. Another method of GAS detection, poly-
merase chain reaction (PCR), typically has higher sensiti-
vity (>90%) and good specificity (>95%) [15,16]. Real-time
quantitative PCR (qPCR) assays provide information on
bacterial cell density, which can be used to assess the limit
of detection of other assays such as RADTs, and to
address scientific questions such as the relationship bet-
ween bacterial density and disease severity.
In this study, we screened six candidate PCR assays
using reference isolates and examined the sensitivity and
specificity of two qPCR assays for detecting GAS pha-
ryngitis. We also investigated how clinical data related to
GAS prevalence and bacterial load.
Methods
Study participants
This was a prospective observational study of patients
aged 3 years and older presenting with acute sore throat
to primary care over the winter/spring of 2011 and 2012
in metropolitan Melbourne (Victoria, Australia). Recruit-
ment occurred at three suburban general practices and
the emergency department of Melbourne’s major tertiary
pediatric hospital (Royal Children’s Hospital). Exclusion
criteria were: previous oral antibiotics within the last
week or intramuscular benzathine penicillin in the last
month, history of rheumatic heart disease or post strep-
tococcal glomerulonephritis, hospitalization, immuno-
suppression, obvious alternate diagnosis (such as herpes
gingivostomatitis or hand foot and mouth disease),
language barrier or inability to give consent. Antibiotics
were prescribed to patients at the discretion of the
treating physician. Demographic information, clinical
data and throat swabs were collected at presentation.
Clinical data were used to calculate the McIsaac score
for each patient [9].
Sample collection, detection of GAS by culture, and
emm-typing
Two throat samples were obtained using standard
methods [3], rubbed together to facilitate even distribution
of bacteria, and transported to the Royal Children’s
Hospital laboratory within 48 h (stored at ambient tempe-
rature if processed the same day of collection and at 4°C if
kept overnight). One swab was used for detection of GAS
by culture as previously described [1], with streptococcal
grouping performed with the Prolex Streptococcal
Grouping Latex kit (Pro-Lab Diagnostics, Richmond Hill,
Canada). GAS growth was scored as follows: rare (<10 β-
hemolytic colonies in the first quadrant only), 1+ (≥10 in
the first quadrant only), 2+ (≥10 in the first and second
quadrants only), 3+ (≥10 in the first, second, and third
quadrants only), and 4+ (≥10 in all four quadrants). emm-
typing was performed as described by the Centers for
Disease Control and Prevention (http://www.cdc.gov/ncidod/
biotech/strep/protocol_emm-type.htm) with the following
modifications: 500 nM primer concentration, and PCR
cycling conditions were a 5 min activation at 95°C,
followed by 30 cycles of amplification at 95°C for 15 s,
46.6°C for 30 s, and 72°C for 90 s and a final extension at
72°C for 10 min.
PCR on reference isolates
Primer pairs shown in Table 1 were tested against a panel
of reference isolates shown in Table 2, present in our
culture collection or kindly provided by Prof. Roy Robins-
Browne, The University of Melbourne. Bacterial DNA was
extracted from fresh overnight cultures using a DNeasy
Blood and Tissue kit (Qiagen, Doncaster, Australia). PCRs
were performed in 25 μl reactions containing appro-
ximately 10 ng genomic DNA, 0.125 U Amplitaq Gold
DNA Polymerase, 1X PCR Gold Buffer (Applied Bio-
systems, Mulgrave, Australia), 2.0 mM MgCl2, 400 nM
forward and reverse primers (Sigma-Aldrich, Sydney,
Australia), and 200 μM each deoxynucleoside triphosphate
(Promega, Alexandria, Australia). PCR cycling conditions
were an initial 5 min at 95°C step, followed by 35 amplifi-
cation cycles of 95°C for 30 s, 64°C for 30 s, and 72°C for
45 s, and a final extension at 72°C for 7 min. PCR pro-
ducts were examined by gel electrophoresis.
Primer and dual-labeled probe sequences for the speB
and spy1258 qPCR assays are shown in Table 1. qPCRs
were performed on reference isolates in duplicate 25 μl
reactions containing approximately 0.4 ng genomic
DNA, 100 nM forward and reverse primer, 150 nM
probe (Eurogentec, Seraing, Belgium), and 1X Brilliant
III Ultra-Fast QPCR master mix (Agilent Technologies,
Santa Clara, USA) on a Stratagene Mx3005 realtime
PCR instrument with an initial activation of 95°C for
3 min followed by 35 cycles of 95°C for 20 s and 60°C
for 20 s.
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qPCR validation on clinical samples
The swab used for qPCR was stored in STGG media
[20] at −80°C until use. Lysis and DNA extraction
from a 100 μl aliquot was performed as previously
described [21]. qPCR reactions were performed in
triplicate using 1 μl of DNA in each qPCR assay as
described above. DNA extracted from pure cultures of
S. pyogenes IGL 6 was used for standard curves to
calculate genome equivalents/μl of GAS. Bacterial load
data are reported as CFU/ml (assuming one genome
per Colony Forming Unit and a GAS genome size of
1.8 Mb).
Table 1 PCR assays selected for screening reference isolates

























*probes used for quantitative PCR assays only.
Table 2 PCR and qPCR results for streptococcal reference isolates
PCR assay* qPCR assay**
Species and strain speB(1) speB(2) parE spy1258(1) spy1258(2) spy1857
speB spy1258
ct value ct value
S. pyogenes IGL 1 + + - + + + 19.5 19.9
S. pyogenes IGL 6 + + - + + + 21.1 20.2
S. pyogenes IGL 13 + + - + + + 21.6 20.3
S. pyogenes IGL 165 + + - + + + 21.2 20.4
S. pyogenes IGL 181 + + +\- + + + 19.5 19.6
S. pyogenes ATCC BAA-572 + + +\- + + + 21.1 20.7
S. pyogenes IRP 187 + + - + + + 20.2 19.9
S. pyogenes 85RP187 + + + + + + 21.1 20.0
S. mitis PMP933 +\- +\- NS +\- +\- +\- No Ct No Ct
S. mitis PMP934 +\- +\- NS +\- +\- +\- No Ct 34.8
S. mitis PMP16 +\- +\- - +\- +\- +\- No Ct No Ct
S. pneumoniae ATCC 6305 - - + - - - No Ct No Ct
S. agalactiae ATCC 13813 - - NS - - + No Ct No Ct
S. agalactiae GBS78 +\- - NS - +\- + No Ct No Ct
S. agalactiae GBS79 - - - +\- +\- + No Ct No Ct
S. sanguis NTCT7864 - - NS - - - No Ct No Ct
S. mutans PMP935 - - NS - - + No Ct No Ct
* + = strong PCR product at expected size; +/− = weak PCR product at expected size; NS = non-specific (PCR product at unexpected size and/or multiple PCR
products); - = no PCR product.
** Cycle threshold (Ct) values are reported as the mean of duplicate wells containing 0.4 ng genomic DNA.
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Statistical analysis
Analyses were conducted using Prism 5.04 (GraphPad
Software, Inc., La Jolla, USA). Student’s t test were used
to compare normally distributed data and Mann-
Whitney and Kruskal-Wallis tests used for data that did
not show normal distribution. The chi-square test for
trend was used to assess GAS prevalence and McIsaac
scores. Spearman's rank correlation coefficient was used
to examine associations between bacterial loads by qPCR
and plate growth scores and bacterial loads by qPCR
and McIsaac scores. McIsaac scores and plate growth
scores were examined using the Pearson correlation
coefficient and chi-square test for trend. P values < 0.05
were considered statistically significant.
Ethical approval
The study was performed in accordance with the Decla-
ration of Helsinki and was approved by the Royal
Children’s Hospital Melbourne Human Research Ethics
Committee HREC 31151 and 32080. Prior to enrolment in
the study, informed consent was given by participants or
by a parent/guardian for participants under the age of 18.
Results
Patient characteristics
The 127 participants included 60 females and 67 males;
91 were children and 36 were adults. Ages ranged from
3 to 72 years with a mean age of 9 y for children and
38 y for adults.
PCR on reference isolates
The six primer pairs (Table 1) initially tested in our
collection of reference streptococcal species (Table 2)
targeted four GAS genes or genetic regions (speB, parE,
spy1258, and spy1857). For two target genes (speB and
spy1258), published primers resulted in a product size
larger than recommended for qPCR, so alternative
primers generating a shorter product were designed and
tested. Initial qualitative PCR revealed that the parE
assay had limited sensitivity for GAS, whereas the
spy1857 detected several non-group A streptococcal
species (Table 2). S. mitis displayed some cross-reactivity
for all assays tested. Based upon these results, two assays
targeting speB (encoding a cysteine protease [22]) and
spy1258 (encoding a putative transcriptional regulator
[19]) were selected for qPCR assay development. The
optimal number of qPCR cycles was determined to be
35 to avoid false positive results with S. mitis, S. sanguis
or S. agalacticae. Only one isolate of S. mitis showed
faint cross-reactivity for the spy1258 assay (Ct of 34.8;
Table 2). The limit of detection for both qPCR assays
was 24 genome equivalents/μl, as this corresponded to
the lowest value on the standard curve that consistently
resulted in a Ct value <35.
Culture and qPCR results from clinical samples
Of the 127 throat samples analyzed, 24 (18.9%) were
positive for GAS by culture. All 24 positive samples
came from children; therefore, the GAS-positive propor-
tion in this age group was 26%. A total of nine different
emm types were identified, with emm89 (6 isolates), emm3
(5 isolates), emm28 (4 isolates) the most common. Other
emm types were emm12.0 (3 isolates), emm1 (2 isolates),
and emm81, emm75, emm9, and emm87 (1 isolate each).
Two new emm subtypes, emm3.87 and emm12.67, were
discovered.
In comparison with culture results, the speB qPCR
had 100% sensitivity and specificity, whereas the spy1258
qPCR had 87% sensitivity and 100% specificity (Table 3).
None of three samples positive for either group C or G
streptococci were positive with our qPCR assays. The
three samples for which the spy1258 qPCR gave a false
negative result were from GAS type emm3 (two isolates)
and emm28 (one isolate) and the bacterial plate growth
scores ranged from 1+ to 3 +.
GAS loads were then estimated using speB qPCR.
GAS bacterial loads ranged from 2.9 × 104 to 1.3 × 107
CFU/ml, with a mean of 1.1 × 106 CFU/ml. GAS loads
by qPCR positively correlated with plate growth scores
(Figure 1A; P = 0.01).
Symptom severity
Overall, mean McIsaac scores were significantly higher
for patients positive for GAS (2.7, 95% CI: 2.3, 3.1) than
those who were GAS negative (1.6, 95% CI: 1.4, 1.9).
This is in keeping with recently published data from the
United States (Table 4; [23]). Of note, there was no
association between McIsaac score and bacterial loads as
determined by qPCR (Figure 1B; P = 0.39) or by plate
growth score (P = 0.08).
Discussion
In this study, we screened six qualitative PCR assays for
GAS identification and selected two candidate qPCR
assays, whose ability to detect GAS pharyngitis was com-
pared to the current gold standard, culture of a throat
swab on blood agar. The speB qPCR assay displayed 100%
sensitivity and specificity, and bacterial load data were
consistent with semi-quantitative measurements of plate














87 (68, 96) 100 (96, 100)
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* 95% confidence intervals (Wald method) shown in parentheses.
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growth. It is unclear why spy1258 had lower sensitivity, as
the failure to detect three GAS isolates appears unrelated
to bacterial load or emm type. However, no internal
control for PCR inhibition was used, so it is possible that
inhibition may have contributed to the reduced sensitivity
of the spy1258 assay. Although the speB qPCR had excel-
lent sensitivity and specificity, this assay would require
further optimization to be used as a rapid diagnostic tool
given the current lengthy DNA extraction protocol
(optimized to maximize DNA yields). The LightCycler
PCR assay for GAS detection was developed as a diagnos-
tic tool [16], but unlike the speB qPCR assay described
here, it is not typically performed with a standard curve
and does not provide quantitative data on bacterial loads.
Differentiation between acute GAS pharyngitis and
pharyngeal carriage remains a challenge and further
studies should include asymptomatic carriers. Potential
differences in bacterial load between GAS carriage and
GAS infection could be evaluated using speB qPCR in a
larger, population-based study. It is likely that other
differences between the carrier and infective state, such
as host response or presence of virulence factors, will
also be important. In this study, we did not see a corre-
lation between symptom severity as indicated by McIsaac
score and GAS bacterial load as determined by qPCR or
by plate growth scores. Although variation in throat swab-
bing techniques can impact the ability to evaluate bacterial
loads, in this study, all samples were collected in a consist-
ent manner by two trained co-investigators. A recent re-
port by Cohen et al. [24] suggested that heavier plate
growth was associated with a trend towards higher
McIsaac scores in children with pharyngitis. However, the
reported P value was 0.09 and plate growth scored as ei-
ther heavy (3+) or light (1+ and 2+). In another study by
the same group that included asymptomatic children,
throat swabs from asymptomatic carriers of GAS were less
likely to have heavy plate growth than swabs from children
with GAS pharyngitis [25]. The link between lower bacte-
rial load and the carrier state should be further investigated
by quantitative methods such as the speB qPCR. This assay
may also help in assessing whether RADT-negative,
culture-positive children may represent GAS carriers.
The proportion of children with sore throat with a
GAS positive culture in our study (26%) is within the
15-30% range typically reported [26] and is similar to
earlier studies performed in metropolitan Melbourne
[1,27]. The emm types identified were also similar to
those reported in a previous study in Melbourne [1] and
are among those most common in high-income coun-
tries [28,29].
Conclusions
This study identified speB qPCR as a highly sensitive
and specific assay for detecting GAS in throat swabs.
The assay may be useful as a diagnostic tool in the
future, allowing accurate identification of patients with
GAS sore throat. In addition, further investigation into
the relationship between bacterial load as determined by



































Figure 1 GAS bacterial loads, plate growth, and symptom severity (McIsaac score). (A). GAS bacterial loads as determined by speB qPCR by
plate growth score. P = 0.01. (B). GAS bacterial loads as determined by speB qPCR by McIsaac score. P = 0.39. For both A and B, each data point
represents CFU/ml data from one patient. Nonlinear regression curves are shown in black and P values calculated using Spearman’s correlation test.




Total GAS positive Estimated risk of GAS
n (%)* n (%)+ (%) [23]
≤0 25 (20) 0 (0) 8-9
1 22 (17) 1 (4) 13-14
2 40 (31) 11 (27) 23-23
3 27 (21) 6 (22) 37-37
≥4 13 (10) 6 (46) 55-56
* % of total patients with the corresponding McIsaac score.
+ % of patients with the corresponding McIsaac score who were GAS positive.
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